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Age-related macular degeneration (AMD, OMIM 
603075) is the most common cause of vision loss and irrevers-
ible blindness among the elderly in the Western world [1]. A 
major hallmark of AMD is the appearance of drusen in the 
macula accompanied by loss of sharp and central vision with 
advancing disease [2]. Cuticular drusen (CD, OMIM 126700), 
also termed “basal laminar drusen” or “early adult-onset, 
grouped drusen,” is a clinical subtype of AMD, characterized 
by the fundoscopic findings of innumerable, small (25–75 
µm), slightly raised, round drusen, scattered throughout the 
central and peripheral retina [3]. CD commonly appear in 
early adulthood, and are readily visualized with fluorescein 
angiography (FA). In more advanced stages, the large number 
of CD present as a typical “stars-in-the-sky” appearance in 
the early phases of the angiogram [4]. Approximately 10% of 
AMD cases display the CD phenotype [5].
The early age of onset and the clustering of the CD 
phenotype in families implies a large genetic contribution 
to the development of CD [5-8]. This is supported by the 
observation that heterozygous mutations in the complement 
factor H (CFH) gene (ID 3075; OMIM 134370) segregate 
with the CD phenotype in multiplex families [5,8]. Common 
variants in and near the CFH gene have been associated with 
CD and with AMD [6,7]. In addition, a rare, highly penetrant 
variant (p.Arg1210Cys) in the CFH gene has been associated 
with AMD [9,10]. However, the p.Arg1210Cys variant was 
not detected in an Icelandic cohort or in the Han Chinese 
population [11,12]. This suggests that the rare p.Arg1210Cys 
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Purpose: Age-related macular degeneration (AMD) and cuticular drusen (CD), a clinical subtype of AMD, have been 
linked to genetic variants in the complement factor H (CFH) gene. In this study, we aimed to investigate the frequency 
of rare variants in the CFH gene in 180 cases with CD. In addition, we aimed to determine the frequency of a previously 
reported rare, highly penetrant CFH variant (p.Arg1210Cys) in a Dutch-German non-CD-type AMD case-control cohort, 
and to describe the phenotype of patients carrying the p.Arg1210Cys variant.
Methods: Study subjects were selected from the European Genetic Database (EUGENDA), a joint AMD database of the 
Radboud University Medical Centre and the University Hospital of Cologne, and graded at the Cologne Image Reading 
Centre and Laboratory (CIRCL). Additionally, two CD cases were recruited from the VU Medical Centre in Amsterdam. 
The CFH gene was analyzed in 180 CD cases with Sanger sequencing. All identified variants were analyzed for potential 
damaging effects with prediction software tools Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping 
(PolyPhen). In addition, we genotyped the p.Arg1210Cys variant in 813 non-CD type AMD cases and 1175 controls.
Results: Sequencing identified 11 rare, heterozygous missense variants, one frameshift variant, and one splice accep-
tor site variant in 16 CD cases. The p.Arg1210Cys variant was identified in two CD cases but was not identified in our 
Dutch-German non-CD-type AMD case-control cohort.
Conclusions: The present study identified the presence of rare variants in the CFH gene in 16 (8.8%) of 180 patients 
with the CD subtype of AMD. The carriers of rare CFH variants displayed a significantly earlier age at onset than non-
carriers (p=0.016). The rare missense variant p.Arg1210Cys was identified in two CD cases, but was not detected in 
813 non-CD type AMD cases or in the 1,175 controls of our Dutch-German cohort. The current study suggests that the 
p.Arg1210Cys variant may be restricted to a subset of patients with the CD subtype of AMD. Detailed clinical pheno-
typing, including fluorescein angiography, of patients with AMD carrying the p.Arg1210Cys variant in other cohorts is 
required to confirm this finding.
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variant is not consistently associated with AMD among 
different populations.
In this study, we aimed to investigate the frequency 
of rare variants in the CFH gene in 180 cases with CD. In 
addition, we aimed to determine the frequency of the rare 
highly penetrant p.Arg1210Cys variant in a Dutch-German 
non-CD type AMD case-control cohort, and to describe the 
phenotype of patients carrying the p.Arg1210Cys variant.
METHODS
EUGENDA Study: The study participants were recruited from 
the European Genetic Database (EUGENDA), a multicenter 
database consisting of subjects from the Nijmegen area, the 
Netherlands and the Cologne area, Germany (Table 1). In 
addition, two CD cases were recruited at the VU Medical 
Centre in Amsterdam. All subjects analyzed in this study 
are Dutch and German and are of Caucasian descent. 
All subjects underwent ophthalmological examinations, 
and AMD staging was performed by the Cologne Image 
Reading Centre and Laboratory (CIRCL). CD was classi-
fied as a symmetric distributed pattern in both eyes of at 
least 50 scattered, uniformly-sized, small (25–75 µm), and 
hyperfluorescent drusen on FA in each eye, with a minimum 
of 20 drusen located outside the Wisconsin age-related macu-
lopathy grading template [6,13]. AMD was classified by the 
presence of at least 15 intermediate (63–124 μm) drusen or 
at least one large (≥125 μm) druse in the Early Treatment 
Diabetic Retinopathy Study (ETDRS) grid (intermediate 
AMD) or geographic atrophy or choroidal neovascularization 
secondary to AMD (advanced AMD). Control subjects were 
≥65 years of age and did not display AMD, which includes 
subjects without drusen, with only small drusen (<63 µm) or 
with pigmentary abnormalities alone or combined with less 
than 10 small drusen. Early AMD cases with ≥10 small drusen 
and pigmentary abnormalities or 1–14 intermediate drusen 
were excluded. The participants’ age at onset was noted as 
the age at which first visual complaints were experienced.
The EUGENDA study was approved by the local research 
ethics committees (Commissie Mensgebonden Onderzoek 
Regio Arnhem-Nijmegen, the Netherlands, and the Ethics 
Committee of the University Hospital Cologne, Germany). 
Written informed consent was obtained from all participants, 
and the study was performed in accordance with the tenets 
of the Declaration of Helsinki. The study was adhered to the 
ARVO statement for the use of human subjects in ophthalmic 
and vision research.
Sequencing: Sanger sequencing of the CFH (NM_000186) 
gene was performed in 178 CD cases from the EUGENDA 
database and two CD cases from Amsterdam. Primers were 
designed to amplify all 22 exons and flanking intron-exon 
junctions with Primer3 software (Appendix 1). PCR were 
performed, and amplification products were sequenced using 
an automated sequencer (BigDye Terminator, version 3, 3730 
DNA analyzer; Applied Biosystems, Waltham, MA). All 
sequencing chromatograms were compared to the reference 
sequence using ContigExpress (Vector NTI Advance, Version 
11.0, Life Technologies, Waltham, MA). Each newly identified 
variant was confirmed with a second independent PCR and 
bidirectional Sanger sequencing. All identified variants were 
annotated based on the Human Genome Variation Society 
(HGVS) nomenclature. Variants with a minor allele frequency 
(MAF) <1% were considered rare variants. The number of 
carriers of rare variants discovered in the CD cohort (n=180) 
was compared to the general population (n=4300) using data 
from Exome Variant Server (EVS). Rare coding (missense, 
frameshift, and nonsense) and splice site variants in the CFH 
gene were used in the analysis. The average age at onset of the 
patients with CD were compared in carriers of rare CFH vari-
ants (n=16; age at onset known=13) versus non-carriers of rare 
CFH variants (n=164; age at onset known=64). The predicted 
effects of identified missense variants were examined using 
Polymorphism Phenotyping (PolyPhen) and Sorting Intol-
erant from Tolerant (SIFT) [14,15].
Table 1. Demographics of sTuDieD subjecTs of The eugeNDa cohorT.
Variables CD Intermediate AMD Advanced AMD Controls
Number (Total) 180 207 606 1175
Mean age (±SD) 70±13.7 74±6.8 77±7.7 70±5.9
Gender
Male 59 (32.8%) 80 (38.6%) 251 (41.4%) 504 (42.9%)
Female 121 (67.2%) 127 (61.4%) 355 (58.6%) 671 (57.1%)
CD: Cuticular drusen; AMD: Age-related macular degeneration; SD: Standard deviation
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Genotyping: The CFH p.Arg1210Cys variant was genotyped 
in 813 non-CD type AMD cases and 1,175 controls from 
the EUGENDA database using a competitive allele-specific 
PCR assay (KASPar SNP Genotyping System, KBiosci-
ences, Teddington, UK). KASPar genotyping was performed 
according to the manufacturer’s protocol in a volume of 4 µl 
containing 10 ng of genomic DNA, 2.5 µl of 2X reaction mix, 
and 0.069 µl of assay (Appendix 2). Thermal cycling condi-
tions included a preincubation step at 94 °C for 15 min, 20 
cycles of 94 °C for 10 s, 57 °C for 5 s, 72 °C for 10 s, followed 
by 23 cycles of 94 °C for 10 s, 57 °C for 20 s, 72 °C for 40 s. 
Plates were analyzed on a 7900 Fast Real-Time PCR system 
(Applied Biosystems).
RESULTS
Through sequencing of the exons and flanking intron-exon 
boundaries of the CFH gene in 180 unrelated CD cases, 13 
heterozygous rare variants in 16 cases (8.8%) were identified 
(Table 2). Of these 13 variants, 11 were missense variants, 
one was a frameshift variant (p.Ala301Asnfs*25), and one 
was a splice acceptor site variant (c.428–2A>G). Seven vari-
ants (c.428–2A>G, p.Ala161Ser, p.Ala173Gly, p.Arg175Gln, 
p.Ser193Leu, p.Ala301Asnfs*25, and p.Trp379Arg) were not 
present in public genetic variant databases (dbSNP, ESP6500/
EVS) and therefore represent rare, unique variants. Six vari-
ants (p.Leu3Val / rs139254423, p.Ile216Thr/rs183474263, 
p.Gln400Lys/rs201671665, p.Gln950His/rs149474608, 
p.Thr956Met/rs145975787, and p.Arg1210Cys/rs121913059) 
had low reported MAFs in these databases (MAFs<0.001). 
The total number of carriers of rare CFH variants in the 
patients with CD (16 (8.8%) of 180) is significantly higher 
than the total number of carriers of rare CFH variants in the 
general population (185 (4.3%) of 4300; p=0.008, Fisher’s 
test). The mean age at onset in carriers of rare CFH variants 
(57.2±16.8 years) is significantly earlier than non-carriers of 
rare CFH variants (66.1±10.8 years; p=0.016, Student t test). 
Using the online prediction algorithms SIFT and PolyPhen, 
potential damaging effects of the missense variants were 
assessed. Three missense variants (p.Ser193Leu, p.Trp379Arg 
and p.Gln950His) showed a consistent deleterious and 
damaging score by both PolyPhen and SIFT, while three 
variants were predicted deleterious or damaging by one of 
the prediction algorithms. Five missense variants were not 
predicted to be deleterious or damaging by either algorithm, 
including the p.Arg1210Cys variant.
The p.Arg1210Cys variant was identified in two unre-
lated individuals with CD. To test for a possible association 
of the p.Arg1210Cys variant in our Dutch-German non-CD 
type AMD case-control cohort, we genotyped this variant in 
813 cases and 1175 controls from the EUGENDA database 
(Table 1). The p.Arg1210Cys variant was not found in our 
genotyped cohort, except in the two patients with CD in 
whom the p.Arg1210Cys variant was identified with sequence 
analysis of the CFH gene.
Both individuals carrying the p.Arg1210Cys variant 
presented with hyperfluorescent drusen on FA, typical of the 
CD subtype of AMD (Figure 1). In case 1, drusen were first 
noted at 50 years, with both eyes displaying numerous small 
drusen in the posterior pole and the peripheral retina (Figure 
1A–D). Case 2 had onset of visual impairment at 64 years and 
presented with numerous small drusen in the posterior pole 
in both eyes. Furthermore, case 2 displayed a large fibrotic 
scar in the right eye (Figure 1E,G), pigmentary changes, and 
an occult choroidal neovascularization in the left eye (Figure 
1F,H).
DISCUSSION
The present study identified the presence of rare variants 
(MAF<1%) in the CFH gene in 16 (8.8%) of 180 patients 
diagnosed with the CD subtype of AMD. This number is 
significantly higher than the number of carriers of rare CFH 
variants in the general population (4.3%, p=0.008). This 
study showed that carriers of rare CFH variants display an 
earlier age at onset than non-carriers of rare CFH variants 
(p=0.016). The rare missense variant p.Arg1210Cys was 
identified in two CD cases, but was not detected in the 813 
non-CD-type AMD cases and 1,175 controls of our Dutch-
German cohort. The p.Arg1210Cys variant was previously 
found to be highly associated with AMD in North American 
cohorts, with a frequency in patients with AMD of 40/2,423 
(1.65%) [10] and 23/2,335 (0.99%) [9], respectively. However, 
the p.Arg1210Cys variant was not detected in an Icelandic 
cohort (consisting of 1,143 patients with AMD) or in a Han 
Chinese cohort (consisting of 258 patients with AMD) [11,12].
The current study suggests that the p.Arg1210Cys variant 
may be restricted to a subset of patients with AMD with CD. 
Since the cohort of patients with CD analyzed in our study 
was too small to reliably test for an association, this finding 
must be confirmed in additional cohorts of patients with CD, 
and/or by detailed clinical phenotyping of patients with AMD 
carrying the p.Arg1210Cys variant using FA. An under- or 
overrepresentation of patients with AMD with CD-like char-
acteristics between cohorts might explain the discrepancy 
in the p.Arg1210Cys association observed among the North 
American [10], Icelandic [11], Han Chinese [12], and Dutch-
German cohorts. However, the distribution of low-frequency 
alleles vary among populations, since they tend to be the 
result of recent mutations and are expected to geographically 
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cluster around the location at which the mutation first arose 
[16]. The frequency of disease-causing variants can differ 
significantly among populations [17] or can even be restricted 
to a geographic region [18].
The CFH protein is an important regulator of the alter-
native pathway of the complement cascade that plays a key 
role in the clearance of pathogens and immune complexes, 
and modulates adaptive immunity [19]. CFH is composed 
of 20 sequential complement control protein (CCP) domains 
(Figure 2). Five of the identified rare variants (p.Ala161Ser, 
p.Ala173Gly, p.Arg175Gln, p.Ser193Leu, and p.Ile216Thr) 
are clustered within the N-terminal domains CCPs 1–4. This 
region has been demonstrated to be involved in cofactor 
activity [20], suggesting that these variants potentially 
have an impact on CFH cofactor activity. Two variants, 
p.Trp379Arg and p.Gln400Lys, are located within the CCP6 
and CCP7 domains, respectively, close to the common 
p.Tyr402His [21] AMD risk variant, which causes defective 
heparin-binding properties [20]. This raises the possibility 
that these variants may exert a similar effect. Three variants 
(p.Gln950His, p.Thr956Met, and p.Arg1210Cys) are clustered 
in the C-terminal CCP domains 16–20. Functional studies 
have demonstrated that these four C-terminal CCP domains 
are necessary for the host cell recognition or discrimination 
properties of CFH [22]. In addition, we identified one frame-
shift (p.Ala301Asnfs*25) variant and one splice-acceptor 
site (428–2A>G) variant, which are predicted to abolish CFH 
function.
Notably, not all missense variants identified in this study 
were predicted by SIFT and PolyPhen to be pathogenic. In 
particular, this is the case for the p.Arg1210Cys variant, 
which was not predicted to be deleterious or damaging by 
either algorithm. However, functional studies have demon-
strated that the p.Arg1210Cys variant compromises CFH 
function, as the mutant protein exhibits defective binding to 
C3d, C3b, heparin, and endothelial cells, and forms a covalent 
interaction with human serum albumin [10,23-26]. Therefore, 
although prediction software tools such as SIFT and PolyPhen 
Table 2. rare sequeNce variaNTs iDeNTifieD iN The CFH geNe iN 180 cD cases.
Number 
of cases
Nucleo-
tide change Protein change SNP Id
MAF 
(%) CD 
cases
EVS/
dbSNP
Previous 
disease 
associa-
tions
Prediction algorithms
SIFT PolyPhen2
1 c.7C>G p.Leu3Val rs139254423 0.27 0.02 Novel Tolerated (0.06) Damaging (0.91)
1 c.428–2A>G Splice-acceptor site NA 0.27 0 Novel NA NA
1 c.481G>T p.Ala161Ser NA 0.27 0 Novel Tolerated (0.17) Benign (0.09)
1 c.518C>G p.Ala173Gly NA 0.27 0 Novel Deleterious (0.03) Benign (0.08)
1 c.524G>A p.Arg175Gln NA 0.27 0 Novel Tolerated (0.17) Benign (0.00)
1 c.578C>T p.Ser193Leu NA 0.27 0 Novel Deleterious (0.0) Damaging (0.99)
1 c.647T>C p.Ile216Thr rs183474263 0.27 0.001 Novel Tolerated (0.19) Benign (0.003)
1 c.901_902del p.Ala301Asnfs*25 NA 0.27 0 Novel NA NA
1 c.1135T>C p.Trp379Arg NA 0.27 0 Novel Deleterious (0.0) Damaging (1.0)
2 c.1198C>A p.Gln400Lys rs201671665 0.55 0.01 aHUS [29] Tolerated (0.94) Benign (0.01)
2 c.2850G>C p.Gln950His rs149474608 0.55 0.61 aHUS [28] Deleterious (0.0) Damaging (0.80)
1 c.2867C>T p.Thr956Met rs145975787 0.27 0.16 aHUS [30] Tolerated (0.38) Damaging (0.96)
2 c.3628C>T p.Arg1210Cys rs121913059 0.55 0.02
aHUS/
AMD 
[10,24]
Tolerated (0.05) Benign (0.02)
MAF: Minor Allele Frequency SIFT: Sorting Intolerant from Tolerant (Intolerance ≤0.05) PolyPhen2: Polymorphism Phenotyping (score 
0→1).
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may assist in assessing potential damaging rare variants, 
functional validation of CFH mutant proteins is needed to 
properly assess the functional consequence of these genetic 
variations.
The majority of the identified variants were not present in 
public databases and have not been previously linked to other 
diseases, demonstrating that many CFH variants are novel 
and unique for individual patients. The number of carriers 
of rare variants is significantly higher in patients with CD 
than the number of carriers in the general population (EVS; 
p=0.008). The carriers of rare CFH variants displayed an 
earlier age at onset than non-carriers (p=0.016). This empha-
sizes the importance of a sequence analysis of the entire 
CFH coding region and the splice junction of the CFH gene 
to identify the causative allele, in particular in individuals 
with the CD subtype of AMD. The p.Arg1210Cys variant has 
previously been demonstrated to confer a high risk of devel-
oping AMD [10], underscoring its pathogenicity. However, 
Figure 1. Fundus photographs and 
f luorescein angiographs of two 
cases carrying the Arg1210Cys 
var iat ion. Case 1 displayed 
numerous small drusen (arrow) 
in the posterior pole and in the 
peripheral retina in both eyes. A, 
B: Color fundus photographs of the 
posterior pole and the periphery of 
the left eye, respectively, of case 1. 
C, D: Fluorescein angiographs of 
the posterior pole and the periphery 
of the left eye, respectively, of case 
1. Case 2 showed small drusen of 
the posterior pole in both eyes. E, 
F: Color fundus photographs of the 
right and left eyes, respectively, of 
case 2. G, H: Fluorescein angio-
graphs of the right and left eyes, 
respectively, of case 2. In addition, 
case 2 displayed a large fibrotic 
scar (G, arrow) in the right eye. In 
the left eye, pigmentary changes 
(F, arrow) and an occult choroidal 
neovascularization (H, arrow) were 
observed.
Figure 2. Schematic representation of factor H and its functional domains. Factor H is composed of 20 complement control protein (CCP) 
domains, and the approximate locations of missense variations are indicated at the top of the diagram. The location of the binding sites for 
C3b (black), cofactor activity (purple), heparin (orange), sialic acid (green), and self-surface recognition (blue bars) are mentioned below 
the diagram.
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two CFH variants were recently identified in a large scale 
sequencing study, and were found not to be associated with 
the disease: p.Glu950His was identified in 9/3,343 patients 
with AMD and 10/1,480 controls (p=0.98), p.Thr956Met was 
identified in 4/3,348 patients with AMD and 6/1,484 controls 
(p=0.99) [27]. This implies that these alleles may not be caus-
ative for AMD. Four of the identified variants (p.Gln400Lys, 
p.Gln950His, p.Thr956Met, and p.Arg1210Cys) were previ-
ously reported in patients with atypical hemolytic uremic 
syndrome (aHUS), a devastating renal disease, supporting 
a previously proposed theory that an allelic overlap exists 
between two distinct pathologies, AMD and aHUS [28-30]. 
Patients with CD carrying aHUS mutations did not have renal 
complaints at the time of recruitment (Appendix 3). This 
suggests that additional genetic variants and/or external trig-
gers determine the disease outcome in individuals carrying 
these alleles.
In conclusion, the present study identified the presence 
of rare variants in the CFH gene in 16 (8.8%) of 180 patients 
with the CD subtype of AMD. The carriers of rare CFH 
variants displayed an earlier age at onset than non-carriers 
(p=0.016). A previously reported rare missense variant, 
p.Arg1210Cys, was identified in two CD cases, but was 
not detected in the 813 non-CD type AMD cases and 1,175 
controls of our Dutch-German cohort. The current study 
suggests that the p.Arg1210Cys variant may be restricted to 
a subset of patients with the CD subtype of AMD. Detailed 
clinical phenotyping, including fluorescein angiography, of 
patients with AMD carrying the p.Arg1210Cys variant in 
other cohorts is required to confirm this finding.
APPENDIX 1: LIST OF CFH GENE SEQUENCING 
PRIMERS.
To access the data, click or select the words “Appendix 1.”
APPENDIX 2: ARG1210CYS VARIANT KASPAR 
PRIMERS.
To access the data, click or select the words “Appendix 2.”
APPENDIX 3: CLINICAL DESCRIPTION OF CD 
PATIENTS WITH RARE VARIANTS IN THE CFH 
GENE.
To access the data, click or select the words “Appendix 3.”
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